Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma- A Cost-Effectiveness Analysis

Mar 1, 2017, 00:00
10.1016/j.jval.2016.09.2397
https://www.valueinhealthjournal.com/article/S1098-3015(16)33765-2/fulltext
Title : Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma- A Cost-Effectiveness Analysis
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)33765-2&doi=10.1016/j.jval.2016.09.2397
First page : 336
Section Title : Comparative Effectiveness Research/HTA
Open access? : Yes
Section Order : 4

Objectives

To perform a cost-effectiveness analysis comparing the use of transarterial radioembolization (TARE) with that of sorafenib in the treatment of patients with intermediate or advanced hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver Cancer staging system.

Methods

Patient-level data were consecutively recorded and collected at three oncology centers in Italy. A propensity score matching was performed to compare patients with similar clinical characteristics who underwent TARE or sorafenib treatment. Clinical data from the matched cohorts were used to populate a Markov model to project, on a lifetime horizon, life years, quality-adjusted life years, and economic outcomes associated with TARE and sorafenib for both intermediate and advanced HCC stages.

Results

Starting from data covering 389 and 241 patients who underwent TARE and sorafenib treatment, respectively, the propensity score matching yielded a total of 308 matched patients. For intermediate-stage patients, the model estimated for TARE versus sorafenib an incremental cost-utility ratio of €3,302/QALY (incremental cost-effectiveness ratio of €1,865 per life year gained), whereas for patients in advanced stage TARE dominated (lower costs and greater health improvements) compared with sorafenib.

Conclusions

From an Italian health care service perspective, TARE could be a cost-effective strategy in comparison with sorafenib for patients with intermediate or advanced HCC. The results from forthcoming randomized controlled trials comparing TARE with sorafenib will be able to confirm or reject the validity of this preliminary evaluation. In the meantime, decision makers can use these results to control and coordinate the diffusion of the technology.

Categories :
Tags :
  • cost-effectiveness
  • hepatocellular carcinoma
  • sorafenib
  • TARE
Regions :
ViH Article Tags :